Evidence map›Paper›PMID 37271889›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

An All-In-One Transient Theranostic Platform for Intelligent Management of Hemorrhage.

Reihaneh Haghniaz, Ankit Gangrade, Hossein Montazerian, Fahimeh Zarei, Menekse Ermis, Zijie Li, Yuxuan Du, Safoora Khosravi, Natan Roberto de Barros, Kalpana Mandal and 7 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Biocompatible Mesoporous Materials for Bone Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. An All-In-One Transient Theranostic Platform for Intelligent Management of Hemorrhage.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Reihaneh HaghniazTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Ankit GangradeTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Hossein MontazerianTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Fahimeh ZareiTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Menekse ErmisTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Zijie LiTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Yuxuan DuTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Safoora KhosraviTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Natan Roberto de BarrosTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Kalpana MandalTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Ahmad RashadTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Fatemeh ZehtabiTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Jinghang LiTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Mehmet R DokmeciTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Han-Jun KimTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Ali KhademhosseiniTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.ORCID 0000-0002-2692-1524
Yangzhi ZhuTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.ORCID 0000-0003-2920-3365
Terasaki Foundation · USUniversity of Southern California · USCalifornia NanoSystems Institute · USKorea University · KRUniversity of British Columbia · CA

Funding

Hemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0M
Engineering highly elastic surgical sealants with hemostatic propertiesR01HL140618 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANNABI, NASIM, KHADEMHOSSEINI, ALI · 2018 to 2021
$2.8M
3D printed muscle-bone organ implant for treating large injuriesR01AR073135 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, JANG, HAE LIN · 2018 to 2022
$2.2M
Oxygen generating bioinks for 3D printed bone implantsR01AR074234 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SHIN, SU RYON · 2018 to 2022
$1.9M
Research Supplements to Promote DiversityR01GM126571 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, YE, JING YONG · 2018 to 2021
$1.3M
Multifunctional dressing for treatment of diabetic woundsR01GM126831 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI DOKMECI, MEHMET REMZI, TAMAYOL, ALI · 2018 to 2021
$1.3M
NHLBI NIH HHS R01 HL137193NHLBI NIH HHS R01 HL140618NIAMS NIH HHS R01 AR073135NIAMS NIH HHS R01 AR074234NIGMS NIH HHS R01 GM126571NIGMS NIH HHS R01 GM126831NIH HHS AR073135NIH HHS AR074234NIH HHS GM126571NIH HHS GM126831NIH HHS HL137193NIH HHS HL140618
6 · The paper itself

Abstract

Developing theranostic devices to detect bleeding and effectively control hemorrhage in the prehospital setting is an unmet medical need. Herein, an all-in-one theranostic platform is presented, which is constructed by sandwiching silk fibroin (SF) between two silver nanowire (AgNW) based conductive electrodes to non-enzymatically diagnose local bleeding and stop the hemorrhage at the wound site. Taking advantage of the hemostatic property of natural SF, the device is composed of a shape-memory SF sponge, facilitating blood clotting, with ≈82% reduction in hemostatic time in vitro as compared with untreated blood. Furthermore, this sandwiched platform serves as a capacitive sensor that can detect bleeding and differentiate between blood and other body fluids (i.e., serum and water) via capacitance change. In addition, the AgNW electrode endows anti-infection efficiency against Escherichia coli and Staphylococcus aureus. Also, the device shows excellent biocompatibility and gradually biodegrades in vivo with no major local or systemic inflammatory responses. More importantly, the theranostic platform presents considerable hemostatic efficacy comparable with a commercial hemostat, Dengen, in rat liver bleeding models. The theranostic platform provides an unexplored strategy for the intelligent management of hemorrhage, with the potential to significantly improve patients' well-being through the integration of diagnostic and therapeutic capabilities.

Indexed as

FibroinsHemostaticsNanowiresAnimalsHemorrhagePrecision MedicineRatsSilverFibroinsHemostaticsSilverantibacterialcapacitive sensorshemostaticsilk spongetheranostic devices

Identifiers

PMID37271889
PMCPMC10460878
OpenAlexW4379376828

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.